Home » Stocks » CVAC

CureVac N.V. (CVAC)

Stock Price: $102.35 USD 8.39 (8.93%)
Updated May 13, 2021 4:00 PM EDT - Market closed
After-hours: $101.00 -1.35 (-1.32%) May 13, 4:28 PM
Market Cap 18.18B
Revenue (ttm) 48.87M
Net Income (ttm) -129.12M
Shares Out 186.22M
EPS (ttm) -0.98
PE Ratio n/a
Forward PE 12.44
Dividend n/a
Dividend Yield n/a
Trading Day May 13
Last Price $102.35
Previous Close $93.96
Change ($) 8.39
Change (%) 8.93%
Day's Open 97.58
Day's Range 95.61 - 102.36
Day's Volume 852,033
52-Week Range 36.15 - 151.80

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

CureVac N.V. (NASDAQ: CVAC) and GlaxoSmithKline Plc (NYSE: GSK) have released positive early data from a preclinical study of its second-generation COVID-19 vaccine with signs that the candidate could a...

Other stocks mentioned: GSK
7 hours ago - Benzinga

BioNTech SE - ADR (NASDAQ: BNTX) shares were trading higher by 8.27% at $198.80 in Monday's premarket session after the company announced a Chinese joint venture to make 1 billion COVID-19 vaccine doses...

Other stocks mentioned: BNTX
3 days ago - Benzinga

The promising data in mice needs to translate into humans.

1 week ago - The Motley Fool

Probably not, but at least one of them could make you thousands over time.

Other stocks mentioned: ARCT, BNTX
1 week ago - The Motley Fool

Here is what you should know about investing in these life changing technologies.

Other stocks mentioned: BNTX, CHNA, CNCR, CRSP, EDIT, IBB, MRNA ...
1 week ago - Zacks Investment Research

Novartis is scaling up facilities to make COVID-19 vaccine doses for German drugmaker CureVac and could boost production beyond levels agreed so far, Chief Executive Vas Narasimhan said on a conference ...

Other stocks mentioned: NVS
2 weeks ago - Reuters

The biotech still has a long way to go to prove itself and justify its current stock valuation.

2 weeks ago - The Motley Fool

A big market is in big need of more vaccines.

3 weeks ago - The Motley Fool

CureVac in Talks With U.S. Over Next-gen Covid Shot: CEO

YouTube video

Apr.16 -- CureVac CEO Franz-Werner Haas says the company aims to produce 300 million doses of their mRNA-based vaccine in 2021 and is in discussions with the U.S. and other countries about supplying nex...

3 weeks ago - Bloomberg Markets and Finance

CureVac to Release Results of Covid Vaccine Trials

YouTube video

Apr.15 -- Kempen & Co Equity Analyst of Life Science Ingrid Gafanhao speaks to Bloomberg's Alix Steel about the Curevac Covid-19 vaccine and it's expected release now that variants are being taken into ...

3 weeks ago - Bloomberg Markets and Finance

PPD, Inc. (NASDAQ: PPD), Immunic, Inc. (NASDAQ: IMUX), Inovio Pharmaceuticals, Inc. (NASDAQ: INO) and CureVac N.V. (NASDAQ: CVAC) are among the healthcare movers on Thursday.

Other stocks mentioned: IMUX, INO
4 weeks ago - Benzinga

The U.K. and EU have pre-ordered up to 455 million doses of CureVac's mRNA vaccine, subject to regulatory approval.

1 month ago - CNBC

CureVac BV (NASDAQ: CVAC) has partnered with Celonic Group, a Contract Development, and Manufacturing Organization, to produce CureVac's mRNA-based COVID-19 vaccine candidate, CVnCoV. The commercial sup...

1 month ago - Benzinga

First challenge infection study in preclinical mouse model to provide evidence for protection against SARS-CoV-2 variant CVnCoV induces robust antibody titers with virus variant neutralizing capacity in...

1 month ago - Accesswire

CureVac BV (NASDAQ: CVAC) plans to expand and further specify the protocols of its ongoing late-stage clinical trials with CVnCoV, its COVID-19 vaccine candidate. CVnCoV efficacy is currently being eval...

1 month ago - Benzinga

The companies in line for the biggest gains – and the shareholders who have already made fortunes

Other stocks mentioned: MRNA, PFE, AZN, BNTX, JNJ, NVAX, SVA
2 months ago - The Guardian

Novartis (NVS) will manufacture the mRNA and bulk drug product for CureVac's COVID-19 vaccine candidate.

Other stocks mentioned: NVS
2 months ago - Zacks Investment Research

Swiss Pharma giant Novartis AG (NYSE: NVS) has agreed to help CureVac BV (NASDAQ: CVAC) produce its experimental COVID-19 vaccine, known as CVnCoV. Novartis plans to manufacture the mRNA molecules that ...

Other stocks mentioned: NVS
2 months ago - Benzinga

Coronavirus vaccine news supply deals and a regulatory filing are in the headlines in Friday's trading session.  US Secures More Vaccine Doses: Moderna Inc (NASDAQ: MRNA) and Pfizer Inc. (NYSE: PFE), th...

Other stocks mentioned: BNTX, MRNA, PFE
3 months ago - Benzinga

mRNA will play a part in pandemic preparedness for the future, CureVac CEO says

YouTube video

Franz-Werner Haas, CEO of CureVac, discusses the future outlook for vaccines.

3 months ago - CNBC International TV

CureVac working on a second generation vaccine to combat Covid variants, CEO says

YouTube video

CureVac CEO Franz-Werner Haas discusses the firm's plans to tackle new Covid-19 variants.

3 months ago - CNBC International TV

The UK government has said it is to join forces with German group CureVac BV (NASDAQ:CVAC) to develop vaccines capable of dealing with mutations in the coronavirus (COVID-19) virus. Britain has initiall...

3 months ago - Proactive Investors

The U.K. has entered into a collaboration accord with CureVac NV (NASDAQ: CVAC) to develop messenger ribonucleic acid (mRNA)-based vaccine candidates against COVID-19 variants.  CureVac will deliver an ...

3 months ago - Benzinga

CureVac Joins GlaxoSmithKline to Make Next-Gen Covid Shot

YouTube video

Feb.03 -- CureVac has joined forces with GlaxoSmithKline Plc to create a next-generation Covid mRNA shot that could help protect against multiple variants of the pathogen, and it's extended a partnershi...

Other stocks mentioned: GSK
3 months ago - Bloomberg Markets and Finance

Shares of CureVac were down 3.1% in premarket trading on Thursday after the German company said it aims to raise $450 million through a follow-up public offering. CureVac, which went public in August, p...

3 months ago - Market Watch

Investors will want to scoop up shares of this diversified drugmaker and coronavirus vaccine developer before it's too late.

Other stocks mentioned: REGN
3 months ago - The Motley Fool

CureVac shares currently trade at $100.6 - down from nearly $150 in early December. The mRNA specialist IPO'd at a price of just $16 in August last year, but shares have spiked in anticipation of an app...

3 months ago - Seeking Alpha

CureVac partners with Bayer to accelerate vaccine production

YouTube video

Franz-Werner Haas, CureVac CEO says it has initiated a phase 2b-3 trial and expects to enroll 35,000 people in Europe and Latin America. He joins 'Closing Bell' to discuss.

Other stocks mentioned: BAYRY
4 months ago - CNBC Television

Data provided further evidence on immunogenicity and protective efficacy of CVnCoV Induction of robust antibody and T cell responses at lower dose than tested in Phase 3 trial Full lung protection of CV...

4 months ago - Accesswire

CureVac (CVAC) gains on a collaboration agreement with Bayer (BAYRY) for further development and supply of its COVID-19 vaccine candidate, CVnCoV.

Other stocks mentioned: BAYRY
4 months ago - Zacks Investment Research

The coronavirus vaccine developer announced a new partnership with a major player on the global pharmaceutical scene.

4 months ago - The Motley Fool

Sometimes you need a little help from a big brother.

Other stocks mentioned: BAYRY
4 months ago - The Motley Fool

CureVac BV (NASDAQ: CVAC) shares have received a nice lift and breached the $100 level for the first time in the new year. What Happened: German coronavirus vaccine maker CureVac said Thursday it has si...

Other stocks mentioned: BAYRY
4 months ago - Benzinga

The shares of CureVac BV (NASDAQ:CVAC) are soaring this morning, up 18.5% at $102.88 at last check.

Other stocks mentioned: BAYRY
4 months ago - Schaeffers Research

LOS ANGELES--(BUSINESS WIRE)---- $CVAC #COVID19--Investor's Business Daily (IBD), a leading financial news and research organization, today announced its list of the 100 Best Companies of 2020. Companie...

4 months ago - Business Wire

Companies enter into a collaboration and services agreement Bayer to support CureVac in numerous areas, including development and supply of CVnCoV CureVac benefits from Bayer's expertise and established...

4 months ago - Accesswire

German biotech firm CureVac has agreed to an alliance with drugmaker Bayer to get global support in seeking approval for its experimental COVID-19 vaccine and for distribution, the two companies said on...

Other stocks mentioned: BAYRY
4 months ago - Reuters

German biotech firm CureVac has agreed to an alliance with drugmaker Bayer to get global support in seeking approval for its experimental COVID-19 vaccine and for distribution, daily Bild reported.

Other stocks mentioned: BAYRY
4 months ago - Reuters

Study to assess safety and immunogenicity of CVnCoV in high-risk population group Study builds on observational epidemiological study TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / December 21, 2020 / ...

4 months ago - Accesswire

Here we discuss four small biotech companies, NVAX, CVAC, VXRT and ARCT, that are making COVID-19 vaccine candidates, which may be approved in 2021, if successfully developed, and bring profits.

Other stocks mentioned: ARCT, NVAX, VXRT
4 months ago - Zacks Investment Research

CureVac (CVAC) doses the first patient in a pivotal study on its COVID-19 vaccine candidate, CVnCoV. Shares rise following this development.

4 months ago - Zacks Investment Research

CureVac N.V. (NASDAQ: CVAC) advanced in the fight against COVID-19 by beginning enrollment in its midstage vaccine candidate study.

4 months ago - 24/7 Wall Street

Tübingen-based CureVac said the Phase 3 trial will include more than 35,000 volunteers in Europe and Latin America

4 months ago - Market Watch

If we judge by return on investment, these two mid-cap biotechs may be the ultimate winners of the coronavirus vaccine race.

Other stocks mentioned: NVAX
5 months ago - The Motley Fool

Here's what you need to know about all of the leaders in the coronavirus vaccine race.

Other stocks mentioned: AZN, BNTX, JNJ, MRNA, NVAX, PFE
5 months ago - The Motley Fool

And it's not too far behind coronavirus vaccine leaders Pfizer and Moderna.

5 months ago - The Motley Fool

The European Union could pay more than $10 billion to secure hundreds of millions of doses of the vaccine candidates being developed by Pfizer-BioNTech and CureVac, an EU official involved in the talks ...

Other stocks mentioned: PFE
5 months ago - Reuters

Enough Pharma Capacity to Vaccinate World by End of 2021: CureVac CEO

YouTube video

Nov.18 -- CureVac Chief Executive Officer Franz-Werner Haas discusses the progress on the biopharmaceutical company's Covid-19 vaccine and scale-up for its production on “Bloomberg Surveillance.”

5 months ago - Bloomberg Markets and Finance

About CVAC

CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidate against COVID-19; CV7202, a prophylactic mRNA-based vaccine, which is in Phase 1 clinical trial for rabies virus glycoprotein; vaccine for lassa yellow fever; vaccine for respirational syncytial virus; CV7301, a second-generation lipid nanoparticle flu vaccine; and vaccines for rota, malaria, and universal influenz... [Read more...]

Industry
Biotechnology
IPO Date
Aug 14, 2020
Stock Exchange
NASDAQ
Ticker Symbol
CVAC
Full Company Profile

Financial Performance

In 2020, CureVac's revenue was $48.87 million, an increase of 180.61% compared to the previous year's $17.42 million. Losses were -$129.12 million, 29.3% more than in 2019.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for CureVac stock is "Buy." The 12-month stock price forecast is 93.82, which is a decrease of -8.33% from the latest price.

Price Target
$93.82
(-8.33% downside)
Analyst Consensus: Buy